🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
1.730
+0.050 (2.98%)
At close: Nov 20, 2026, 4:00 PM EST
1.740
+0.010 (0.58%)
After-hours: Nov 20, 2026, 7:30 PM EST

XBiotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
----4.0118.39
----4.0118.39
Revenue Growth
-----78.20%-58.19%
Cost of Revenue
----0.655.82
Gross Profit
----3.3612.57
Selling, General & Admin
6.988.34.714.666.319.39
Research & Development
40.5247.3937.7632.8531.5428.27
Operating Expenses
47.4955.6942.4737.5137.8537.66
Operating Income
-47.49-55.69-42.47-37.51-34.49-25.08
Interest Expense
--0.09-0.81---
Interest & Investment Income
3.855.689.8110.423.820.47
Currency Exchange Gain (Loss)
-1.333.33-5.531.89-2.8-0.71
Other Non Operating Income (Expenses)
1.030.90.430.88-0.12-0.13
EBT Excluding Unusual Items
-43.94-45.86-38.56-24.31-33.59-25.46
Other Unusual Items
0.560.56----
Pretax Income
-43.38-45.31-38.56-24.31-33.59-25.46
Income Tax Expense
0.210.24-0.030.24-0.69-8.04
Net Income
-43.59-45.54-38.53-24.56-32.9-17.41
Net Income to Common
-43.59-45.54-38.53-24.56-32.9-17.41
Net Income Growth
------
Shares Outstanding (Basic)
303030303030
Shares Outstanding (Diluted)
303030303030
Shares Change
0.02%0.09%0.07%-0.00%1.32%-2.53%
EPS (Basic)
-1.43-1.49-1.26-0.81-1.08-0.58
EPS (Diluted)
-1.43-1.49-1.26-0.81-1.08-0.58
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-41-40.21-32.27-19.09-15.4165.92
Free Cash Flow Per Share
-1.34-1.32-1.06-0.63-0.512.19
Gross Margin
----83.77%68.36%
Operating Margin
-----860.10%-136.36%
Profit Margin
-----820.45%-94.67%
Free Cash Flow Margin
-----384.26%358.38%
EBITDA
-46.23-54-40.73-35.77-31.88-22.43
EBITDA Margin
------121.96%
D&A For EBITDA
1.261.691.751.742.612.65
EBIT
-47.49-55.69-42.47-37.51-34.49-25.08
EBIT Margin
------136.36%
Revenue as Reported
----4.0118.39
SEC Filings: 10-K · 10-Q